CA2875970C - Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases - Google Patents
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases Download PDFInfo
- Publication number
- CA2875970C CA2875970C CA2875970A CA2875970A CA2875970C CA 2875970 C CA2875970 C CA 2875970C CA 2875970 A CA2875970 A CA 2875970A CA 2875970 A CA2875970 A CA 2875970A CA 2875970 C CA2875970 C CA 2875970C
- Authority
- CA
- Canada
- Prior art keywords
- naphthyridin
- oxo
- dihydro
- ethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/041378 WO2013184119A1 (en) | 2012-06-07 | 2012-06-07 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2875970A1 CA2875970A1 (en) | 2013-12-12 |
| CA2875970C true CA2875970C (en) | 2017-07-04 |
Family
ID=49712374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2875970A Active 2034-06-07 CA2875970C (en) | 2012-06-07 | 2012-06-07 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Country Status (28)
| Country | Link |
|---|---|
| EP (3) | EP3722296A3 (https=) |
| JP (1) | JP5883195B2 (https=) |
| KR (1) | KR101652229B1 (https=) |
| CN (3) | CN110433162A (https=) |
| AU (1) | AU2012327210B2 (https=) |
| BR (1) | BR112014030577B1 (https=) |
| CA (1) | CA2875970C (https=) |
| CY (1) | CY1123377T1 (https=) |
| DK (2) | DK3366293T3 (https=) |
| ES (2) | ES2663605T3 (https=) |
| FR (1) | FR22C1013I2 (https=) |
| HR (1) | HRP20200864T1 (https=) |
| HU (2) | HUE049958T2 (https=) |
| IL (1) | IL236110A (https=) |
| LT (2) | LT3366293T (https=) |
| LU (1) | LUC00253I2 (https=) |
| MX (2) | MX372814B (https=) |
| NL (1) | NL301169I2 (https=) |
| NO (1) | NO2022010I1 (https=) |
| PH (2) | PH12018502294B1 (https=) |
| PL (1) | PL3366293T3 (https=) |
| PT (2) | PT3366293T (https=) |
| RS (1) | RS60406B1 (https=) |
| RU (1) | RU2664055C2 (https=) |
| SG (1) | SG11201408133TA (https=) |
| SI (1) | SI3366293T1 (https=) |
| SM (1) | SMT202000302T1 (https=) |
| WO (1) | WO2013184119A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| SG11201805869XA (en) * | 2016-01-11 | 2018-08-30 | Merck Patent Gmbh | Quinolin-2-one derivatives |
| CA3065365C (en) * | 2017-05-30 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR |
| WO2019056990A1 (zh) * | 2017-09-20 | 2019-03-28 | 浙江海正药业股份有限公司 | 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| KR102708177B1 (ko) * | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| EP3938363A1 (en) * | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| US10927111B2 (en) | 2019-05-03 | 2021-02-23 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| US20240075041A1 (en) * | 2019-10-04 | 2024-03-07 | Blueprint Medicines Corporation | Treatment of eosinophilic disorders with avapritinib |
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| HRP20231699T1 (hr) * | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| KR102535840B1 (ko) | 2020-07-31 | 2023-05-23 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도 |
| US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN112625038A (zh) * | 2020-12-31 | 2021-04-09 | 武汉九州钰民医药科技有限公司 | 制备瑞普替尼的方法 |
| WO2022162690A1 (en) * | 2021-01-28 | 2022-08-04 | Dr. Reddy's Laboratories Limited | Process for the preparation of ripretinib and solid state forms thereof |
| CN117561057A (zh) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
| EP4476218A1 (en) * | 2021-12-24 | 2024-12-18 | Assia Chemical Industries Ltd. | Improved processes for the preparation of ripretinib |
| CN114213411B (zh) * | 2022-01-24 | 2023-06-30 | 成都伊诺达博医药科技有限公司 | 一种瑞普替尼的合成方法 |
| US11814384B2 (en) | 2022-02-03 | 2023-11-14 | Kinnate Biopharma Inc. | Inhibtors of Raf kinases |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| DE102006030524A1 (de) * | 2006-07-01 | 2008-01-03 | Koch Transporttechnik Gmbh | Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CN101516379A (zh) * | 2006-09-14 | 2009-08-26 | 迪赛孚尔制药有限公司 | 可用于治疗增殖性疾病的激酶抑制剂 |
| EA200900573A1 (ru) * | 2006-10-20 | 2009-10-30 | АйАрЭм ЭлЭлСи | Композиции и способы для модуляции рецепторов c-kit и pdgfr |
| CA2714700C (en) * | 2008-02-22 | 2013-07-30 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
-
2012
- 2012-06-07 DK DK17208408.9T patent/DK3366293T3/da active
- 2012-06-07 DK DK12878321.4T patent/DK2858646T3/en active
- 2012-06-07 AU AU2012327210A patent/AU2012327210B2/en active Active
- 2012-06-07 PL PL17208408T patent/PL3366293T3/pl unknown
- 2012-06-07 JP JP2015515992A patent/JP5883195B2/ja active Active
- 2012-06-07 SG SG11201408133TA patent/SG11201408133TA/en unknown
- 2012-06-07 CN CN201910368783.1A patent/CN110433162A/zh active Pending
- 2012-06-07 CA CA2875970A patent/CA2875970C/en active Active
- 2012-06-07 WO PCT/US2012/041378 patent/WO2013184119A1/en not_active Ceased
- 2012-06-07 EP EP20161887.3A patent/EP3722296A3/en active Pending
- 2012-06-07 EP EP12878321.4A patent/EP2858646B1/en active Active
- 2012-06-07 CN CN201910368784.6A patent/CN110403938A/zh active Pending
- 2012-06-07 HU HUE17208408A patent/HUE049958T2/hu unknown
- 2012-06-07 ES ES12878321.4T patent/ES2663605T3/es active Active
- 2012-06-07 EP EP17208408.9A patent/EP3366293B1/en active Active
- 2012-06-07 MX MX2014015024A patent/MX372814B/es active IP Right Grant
- 2012-06-07 RS RS20200633A patent/RS60406B1/sr unknown
- 2012-06-07 BR BR112014030577-3A patent/BR112014030577B1/pt active IP Right Grant
- 2012-06-07 CN CN201280075113.7A patent/CN104902895B/zh active Active
- 2012-06-07 PH PH1/2018/502294A patent/PH12018502294B1/en unknown
- 2012-06-07 SI SI201231785T patent/SI3366293T1/sl unknown
- 2012-06-07 SM SM20200302T patent/SMT202000302T1/it unknown
- 2012-06-07 ES ES17208408T patent/ES2797252T3/es active Active
- 2012-06-07 MX MX2020005712A patent/MX392372B/es unknown
- 2012-06-07 RU RU2014153920A patent/RU2664055C2/ru active
- 2012-06-07 KR KR1020157000365A patent/KR101652229B1/ko active Active
- 2012-06-07 LT LTEP17208408.9T patent/LT3366293T/lt unknown
- 2012-06-07 PT PT172084089T patent/PT3366293T/pt unknown
- 2012-06-07 PT PT128783214T patent/PT2858646T/pt unknown
-
2014
- 2014-12-07 IL IL236110A patent/IL236110A/en active IP Right Grant
- 2014-12-09 PH PH12014502757A patent/PH12014502757B1/en unknown
-
2020
- 2020-05-29 HR HRP20200864TT patent/HRP20200864T1/hr unknown
- 2020-06-10 CY CY20201100530T patent/CY1123377T1/el unknown
-
2022
- 2022-04-05 LU LU00253C patent/LUC00253I2/fr unknown
- 2022-04-07 NO NO2022010C patent/NO2022010I1/no unknown
- 2022-04-07 FR FR22C1013C patent/FR22C1013I2/fr active Active
- 2022-04-12 NL NL301169C patent/NL301169I2/nl unknown
- 2022-05-03 LT LTPA2022008C patent/LTC3366293I2/lt unknown
- 2022-05-09 HU HUS2200017C patent/HUS2200017I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2875970C (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| USRE48731E1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| CA2779105C (en) | Kinase inhibitors | |
| CA3118330A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| WO2013134298A1 (en) | Raf inhibitor compounds | |
| EP3152209B1 (en) | Naphthyridinedione derivatives as suppressors of non-sense mutations | |
| KR20190034234A (ko) | 선택적 jak 저해제로서 화합물, 및 이의 염 및 치료학적 용도 | |
| JP2017516829A (ja) | ピリドピリミジンジオン誘導体 | |
| MX2014009524A (es) | Derivados de triazolopiridina como un inhibidor de quinasa tirosina. | |
| HK40039059A (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| RU2804468C2 (ru) | Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний | |
| HK1259893A1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| HK1259893B (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| HK1209345B (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| HK40003405A (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| EA040948B1 (ru) | Селективные ингибиторы jak1 и их применение | |
| HK1230182B (en) | Naphthyridinedione derivatives as suppressors of non-sense mutations | |
| HK1230182A1 (en) | Naphthyridinedione derivatives as suppressors of non-sense mutations | |
| HK1207636B (zh) | 用於治疗病毒感染和另外的疾病的烷基嘧啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141205 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250530 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |